Avapritinib 100mg Tablets

Avapritinib 100mg Tablets represent a precision therapy designed to target specific kinase mutations that drive rare and aggressive hematological and gastrointestinal cancers. Pharmacologically, it is a type 1 inhibitor of the KIT and PDGFRA receptor tyrosine kinases. Unlike many other kinase inhibitors, Avapritinib is chemically engineered to bind to the active conformation of these enzymes.

This specific binding mode allows it to potently inhibit activation loop mutations, most notably the KIT D816V mutation. This particular mutation acts as a “driver” in Systemic Mastocytosis (SM), causing mast cells to proliferate uncontrollably and accumulate in various organs. Standard tyrosine kinase inhibitors often struggle to bind to this mutated form, but Avapritinib 100mg Tablets effectively lock the kinase in an inactive state, halting the signaling pathways responsible for cell survival and proliferation.

Indications / Uses of Avapritinib 100mg Tablets

Avapritinib 100mg Tablets are indicated for the treatment of adult patients with specific genetically defined conditions. The primary FDA-approved indications include:

• Advanced Systemic Mastocytosis (AdvSM): Indicated for adults with aggressive systemic mastocytosis (ASM), systemic mastocytosis with an associated hematological neoplasm (SM-AHN), or mast cell leukemia (MCL). It addresses the underlying driver mutation (KIT D816V) found in the vast majority of these patients.
• Indolent Systemic Mastocytosis (ISM): In lower doses, it is used for adult patients with ISM who have moderate to severe symptoms that are not adequately controlled by symptom-directed therapies.
• Gastrointestinal Stromal Tumors (GIST): Indicated for the treatment of adults with unresectable or metastatic GIST harboring a platelet-derived growth factor receptor alpha (PDGFRA) exon 18 mutation, including PDGFRA D842V mutations. This subset of GIST is notoriously resistant to standard therapies like imatinib.

Key Features

• Targeted Mutation Selectivity: The drug is highly selective for the KIT D816V and PDGFRA D842V mutations, offering efficacy where other TKIs typically fail.
• Potent Mast Cell Reduction: Clinical data shows profound reductions in mast cell burden (measured by serum tryptase levels and bone marrow biopsy), leading to significant symptom relief and organ recovery.
• Oral Administration: The tablet is taken orally once daily on an empty stomach (at least 1 hour before or 2 hours after a meal), facilitating outpatient management.
• Brain Penetration: Avapritinib can cross the blood-brain barrier, which contributes to its therapeutic reach but also necessitates monitoring for central nervous system effects.
• Rapid Response: Reductions in biomarkers like tryptase often occur rapidly, sometimes within the first few weeks of treatment.

Storage for Avapritinib 100mg Tablets

To ensure the stability of Avapritinib 100mg Tablets, proper storage conditions are essential. Store the medication at controlled room temperature, typically between 20°C and 25°C (68°F to 77°F). Brief excursions are permitted between 15°C and 30°C (59°F to 86°F). Keep the tablets in their original container to protect them from moisture. Do not store the medication in humid environments like bathrooms. Ensure the bottle is tightly closed after each use and stored securely out of the reach and sight of children and pets.

Important Note on Avapritinib 100mg Tablets

Treatment with Avapritinib 100mg Tablets requires strict safety monitoring due to specific risks, most notably intracranial hemorrhage (bleeding in the brain). This has been reported in patients, particularly those with low platelet counts (thrombocytopenia). Platelet counts must be monitored prior to initiation and regularly during treatment. Severe thrombocytopenia may require dose interruption or reduction.

Cognitive effects are also a known risk; patients may experience memory impairment, cognitive disorder, confusion, or dizziness. Patients should be advised to avoid driving or operating machinery if they experience these symptoms.

Fluid retention (edema), including periorbital edema (swelling around the eyes) and peripheral edema, is common. Patients should be weighed regularly and monitored for signs of fluid overload. Photosensitivity reactions can occur, so patients should use sunscreen and limit sun exposure.

Avapritinib can cause fetal harm. Females of reproductive potential and males with female partners of reproductive potential should use effective contraception during treatment and for 6 weeks after the final dose. Do not take a missed dose if less than 8 hours remain before the next scheduled dose.